11 June 2018

Designing and Monitoring Anti-NGF Imaging Endpoints

Written by Colin G. Miller


Anti-nerve growth factor (NGF) therapeutics are a new class of powerful analgesics in clinical development. But the FDA put their clinical development on hold in 2012 because joint destruction was observed in a small subset of patients. Pfizer, the leading developer of NGF compounds, needed a way to evaluate all major joints in subjects entering the new Phase III program.


Members of our group have substantial experience in imaging in osteoarthritis and NGF-targeting therapies affected joints in a similar manner, so Pfizer specifically sought us out. The solution was to:

  • Engage a team of radiologists to develop a new radiographic technique to evaluate the joints in the defined patient population.

  • Build and participate in a strong academic team that published a landmark Imaging Atlas in 2015. The book described the technique and now serves as a key clinical reference.

  • Further develop specific inter-reader training and validation techniques to reduce variability in this new arena.  The first reproducibility paper from this study has already been published.


Pfizer conducted a very successful anti-NGF program with all the radiological and MRI reads done in a reproducible and effective manner.

Click here to open a PDF version of this case study.


New call-to-action


Designing Success: Transforming Life Sciences Promotion at a Global Convention

The Scenario A major life sciences product development organization wanted banners to promote their..

Guiding an Entrepreneur Through the Complex Process of Drug Development: A Cannabis Case Study

Overview There are more than 160 ‘rare’ cannabinoids that have been isolated from cannabis and..